Publications by authors named "Steven E Coutre"

67Publications

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

N Engl J Med 2019 08;381(5):432-443

From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1817073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908306PMC
August 2019

Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.

Br J Haematol 2018 01 18;180(1):164-166. Epub 2016 Aug 18.

Department of Medicine, Division of Oncology, Stanford University, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14302DOI Listing
January 2018

Discussion: Managing Risk When Using Idelalisib.

Clin Adv Hematol Oncol 2016 May;14(5 Suppl 8):13

Hematopoietic Stem Cell Transplantation Program, Swedish Cancer Institute, Seattle, Washington.

View Article

Download full-text PDF

Source
May 2016

Evolving Frontline Treatment in Chronic Lymphocytic Leukemia.

Authors:
Steven E Coutre

Clin Adv Hematol Oncol 2016 May;14(5 Suppl 8):5-6

Stanford University Medical Center, Stanford, California.

View Article

Download full-text PDF

Source
May 2016

A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

Br J Haematol 2016 Apr 4;173(2):253-9. Epub 2016 Apr 4.

Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13946DOI Listing
April 2016

Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides.

Am J Surg Pathol 2015 Dec;39(12):1653-60

Departments of *Pathology ‡Medicine (Hematology), Stanford University School of Medicine, Stanford †Department of Pathology, University of California Davis, Sacramento, CA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/ajsp/2015/12000/Idelalisib_asso
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PAS.0000000000000525DOI Listing
December 2015

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

N Engl J Med 2014 Mar 22;370(11):997-1007. Epub 2014 Jan 22.

Weill Cornell Medical College (R.R.F.), Memorial Sloan-Kettering Cancer Center (A.D.Z.), the Department of Medicine, and Columbia University Medical Center (N.L.) - all in New York; U.S. Oncology Research, Springfield, OR (J.P.S.); Stanford University School of Medicine, Stanford (S.E.C.), and Gilead Sciences, Foster City (M.A., D.M.J., L.L.M., D.L., T.M.J., R.D.D.) - both in California; Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC (B.D.C.); Fred Hutchinson Cancer Research Center, University of Washington, Seattle (J.M.P.); St. James's University Hospital, Leeds (P.H.), and Royal Liverpool University Hospital, Liverpool (A.R.P.) - both in the United Kingdom; Hofstra North Shore-LIJ School of Medicine, New Hyde Park, New York (J.C.B.); University of California San Diego, Moores Cancer Center, La Jolla (T.J.K.); Sarah Cannon Research Institute, Nashville (I.F.); Universita Vita-Salute San Raffaele, Instituto Scientifico San Raffaele, Milan (P.G.); David Geffen School of Medicine, University of California Los Angeles, Los Angeles (H.E.); Florida Cancer Specialists, Englewood (T.E.); Centre Hospitalier Lyon-Sud, Pierre-Bénite, France (B.C.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (S.M.); University of Ulm, Ulm (S.S.), and University of Cologne, Cologne (P.C., M.H.) - both in Germany; and University of Texas M.D. Anderson Cancer Center, Houston (S.M.O.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1315226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161365PMC
March 2014

Acute myeloid leukemia, version 2.2013.

J Natl Compr Canc Netw 2013 Sep;11(9):1047-55

From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 4Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 5Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 6Stanford Cancer Institute; 7Massachusetts General Hospital Cancer Center; 8University of Alabama at Birmingham Comprehensive Cancer Center; 9UCSF Helen Diller Family Comprehensive Cancer Center; 10Moffitt Cancer Center; 11UNMC Eppley Cancer Center at The Nebraska Medical Center; 12The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 13St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 14Fox Chase Cancer Center; 15Duke Cancer Institute; 16The University of Texas MD Anderson Cancer Center; 17Huntsman Cancer Institute at the University of Utah; 18The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 19Dana-Farber Cancer Institute; 20Vanderbilt-Ingram Cancer Center; 21Roswell Park Cancer Institute; and 22National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234PMC
http://dx.doi.org/10.6004/jnccn.2013.0127DOI Listing
September 2013

Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia.

Am J Hematol 2012 Jan 4;87(1):45-50. Epub 2011 Nov 4.

Department of Medicine, Division of Hematology, Stanford University School of Medicine, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.22191DOI Listing
January 2012

Optimizing therapy for acute myeloid leukemia.

J Natl Compr Canc Netw 2008 Nov;6(10):1003-16

Department of Medicine, Division of Hematology, Stanford University, Stanford, California 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2008.0076DOI Listing
November 2008

Acute postoperative thrombotic thrombocytopenic purpura following hysterectomy and lymphadenectomy for endometrial cancer.

Gynecol Oncol 2007 Aug 17;106(2):423-6. Epub 2007 May 17.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, 300 Pasteur Drive, HH333, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S009082580700260
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2007.04.005DOI Listing
August 2007

Von Willebrand disease presenting as recurrent hemorrhage after transvaginal oocyte retrieval.

Am J Obstet Gynecol 2007 Apr;196(4):e10-1

Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Stanford Hospital, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajog.2007.01.025DOI Listing
April 2007

Refractory hematuria from amyloidosis successfully treated by splenectomy.

Urology 2006 May;67(5):1085.e13-5

Department of Urology, Stanford University School of Medicine, Stanford, California 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2005.11.048DOI Listing
May 2006

The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

Blood 2004 Apr 20;103(8):2879-91. Epub 2003 Nov 20.

Division of Hematology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA 94305-5821, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2003-06-1824DOI Listing
April 2004

Management of advanced chronic lymphocytic leukemia.

Curr Hematol Rep 2003 Jan;2(1):65-72

Division of Hematology, 703 Welsh Road, Stanford University, School of Medicine, Stanford, CA 94305-5112, USA.

View Article

Download full-text PDF

Source
January 2003

T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).

Hematology 2003 Feb;8(1):1-6

Department of Medicine, Division of Hematology, Stanford University School of Medicine, CA 94305-5112, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1024533021000059465DOI Listing
February 2003

Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia.

Clin Lymphoma 2002 Sep;3(2):105-10

Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/clm.2002.n.016DOI Listing
September 2002